Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Hess, Katharina ^a,b   Ajjan, Ramzi ^b   Phoenix, Fladia ^b   Dobó, József ^c   Gál, Péter ^c   Schroeder, Verena ^b,d  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; LEUCINE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 1; PROTHROMBIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNCLASSIFIED DRUG; VALINE; BLOOD CLOTTING FACTOR; FIBRIN; MASP1 PROTEIN, HUMAN;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; COMPLEMENT SYSTEM; CONTROLLED STUDY; CROSS LINKING; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TURBIDIMETRY; AMINO ACID SUBSTITUTION; ENZYME ACTIVATION; GENETICS; METABOLISM; PHOTOMETRY; PHYSIOLOGY; PROTEIN DEGRADATION;

AMINO ACID SUBSTITUTION; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CARBOXYPEPTIDASE U; ENZYME ACTIVATION; FACTOR XIII; FIBRIN; FIBRINOGEN; HUMANS; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; NEPHELOMETRY AND TURBIDIMETRY; PROTEOLYSIS; PROTHROMBIN;

EID: 84859960939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035690     Document Type: Article

References (45)

1. Opal SM, (2000) Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 28: S77-80.
2. Markiewski MM, Nilsson B, Nilsson Ekdahl K, Mollnes TE, Lambris JD, (2007) Complement and coagulation: strangers or partners in crime? Trends Immunol 28: 184-192.
3. Amara U, Flierl MA, Rittirsch D, Klos A, Chen Hui, et al. (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185: 5628-5636.
4. Hajela K, Kojima M, Ambrus G, Wong KHN, Moffatt BE, et al. (2002) The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 205: 467-475.
5. Gál P, Barna L, Kocsis A, Závodszky P, (2007) Serine proteases of the classical and lectin pathways: similarities and differences. Immunobiology 212: 267-277.
6. Terai I, Kobayashi K, Matsushita M, Fujita T, (1997) Human serum mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1): determination of levels in body fluids and identification of two forms in serum. Clin Exp Immunol 110: 317-323.
7. Thiel S, Jensenius JC, Jensen L, Degn S, (2011) Normal and acute phase variations of MASP-1, an enzyme associated with humoral pattern recognition molecules. Mol Immunol 48: 1710.
8. Krarup A, Wallis R, Presanis JS, Gál P, Sim RB, (2007) Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2: e623.
9. Ambrus G, Gál P, Kojima M, Szilágyi K, Balczer J, et al. (2003) Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and-2: a study on recombinant catalytic fragments. J Immunol 170: 1374-1382.
10. Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, et al. (2011) Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 108: 7523-7528.
11. Møller-Kristensen M, Thiel S, Sjöholm A, Matsushita M, Jensenius JC, (2007) Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. Int Immunol 19: 141-149.
12. Takahashi M, Iwaki D, Kanno K, Ishida Y, Xiong J, et al. (2008) Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway. J Immunol 180: 6132-6138.
13. Kocsis A, Kékesi KA, Szász R, Végh BM, Balczer J, et al. (2010) Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and-2: Significant contribution of MASP-1 to lectin pathway activation. J Immunol 185: 4169-4178.
14. Takahashi M, Ishida Y, Iwaki D, Kanno K, Suzuki T, et al. (2010) Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J Exp Med 207: 29-37.
15. Banda NK, Takahashi M, Levitt B, Glogowska M, Nicholas J, et al. (2010) Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J Immunol 185: 5598-5606.
16. Dobó J, Major B, Kékesi KA, Szabó I, Megyeri M, et al. (2011) Cleavage of kininogen and subsequent bradykinin release by the complement component: Mannose-binding lectin-associated serine protease (MASP)-1. PLoS One 6: e20036.
17. Presanis JS, Hajela K, Ambrus G, Gál P, Sim RB, (2004) Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 40: 921-929.
18. Dobó J, Harmat V, Beinrohr L, Sebestyén E, Závodszky P, et al. (2009) MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J Immunol 183: 1207-1214.
19. Krarup A, Gulla KC, Gál P, Hajela K, Sim RB, (2008) The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim Biophys Acta 1784: 1294-1300.
20. Megyeri M, Makó V, Beinrohr L, Doleschall Z, Prohászka Z, et al. (2009) Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J Immunol 183: 3409-3416.
21. Gulla KC, Gupta K, Krarup A, Gál P, Schwaeble WJ, et al. (2010) Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 129: 482-495.
22. Takahashi K, Chang WC, Takahashi M, Pavlov V, Ishida Y, et al. (2011) Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 216: 96-102.
23. La Bonte LR, Pavlov VI, Tan YS, Takahashi K, Takahashi M, et al. (2012) Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 188: 885-891.
24. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, et al. (1996) Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76: 535-540.
25. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, et al. (2006) Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26: 2567-2573.
26. Collet JP, Park D, Lesty C, Soria J, Soria C, et al. (2000) Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20: 1354-1361.
27. Ajjan R, Lim BCB, Standeven KF, Harrand R, Dolling S, et al. (2008) Common variation in the C-terminal region of the fibrinogen β-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 111: 643-650.
28. Kohler HP, Ariëns RAS, Whitaker P, Grant PJ, (1998) A common coding polymorphism in the factor XIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thromb Haemost 80: 704.
29. Ariëns RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ, (2002) Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100: 743-754.
30. Bajzar L, Morser J, Nesheim M, (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271: 16603-16608.
31. Carter AM, Cymbalista CM, Spector TD, Grant PJ, (2007) Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 27: 2783-2789.
32. Speidl WS, Kastl SP, Huber K, Wojta J, (2011) Complement in atherosclerosis: friend or foe? J Thromb Haemost 9: 428-440.
33. Mikkola H, Muszbek L, Laiho E, Syrjälä M, Hämäläinen E, et al. (1997) Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting partial correct splicing of FXIII A-subunit mRNA. Blood 89: 1279-1287.
34. Trumbo TA, Maurer MC, (2002) Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation. Biochemistry 41: 2859-2868.
35. Jadhav MA, Lucas RC, Goldsberry WN, Maurer MC, (2011) Design of factor XIII V34X activation peptides to control ability to interact with thrombin mutants. Biochim Biophys Acta 1814: 1955-1963.
36. Muszbek L, Bereczky Z, Bagoly Z, Shemirani AH, Katona E, (2010) Factor XIII and atherothrombotic diseases. Semin Thromb Hemost 36: 18-33.
37. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ, (2003) Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361: 1424-1431.
38. Bereczky Z, Balogh E, Katona E, Pocsai Z, Czuriga I, et al. (2007) Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res 120: 567-573.
39. Ryan EA, Mockros LF, Weisel JW, Lorand L, (1999) Structural origins of fibrin clot rheology. Biophys J 77: 2813-2826.
40. Weisel JW, (2004) The mechanical properties of fibrin for basic scientists and clinicians. Biophys Chem 112: 267-276.
41. Wolberg AS, (2007) Thrombin generation and fibrin clot structure. Blood Reviews 21: 131-142.
42. Blombäck B, Hessel B, Hogg D, Therkildsen L, (1978) A two-step fibrinogen-fibrin transition in blood coagulation. Nature 275: 501-505.
43. Schroeder V, Carter AM, Dunne J, Mansfield MW, Grant PJ, (2010) Proinflammatory and hypofibrinolytic phenotype in healthy first-degree relatives of patients with type 2 diabetes. J Thromb Haemost 8: 2080-2082.
44. Howes JM, Richardson VR, Smith KA, Schroeder V, Somani R, et al. (2012) Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res In press.
45. Hess K, Alzahrani S, Mathai M, Schroeder V, Carter AM, et al. (2012) A novel mechanism for hypofibrinolysis in diabetes: The role of Complement C3. Diabetologia In press.